Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cellectis S.A. is a biotechnology company focused on developing innovative gene-editing therapies using its proprietary TALEN technology. The company operates primarily in the United States and Europe, targeting diseases such as cancer and genetic disorders, which positions it uniquely in the expanding field of gene therapy.
Cellectis generates revenue primarily through strategic collaborations with larger pharmaceutical firms, leveraging its TALEN technology for gene editing. The company has a competitive advantage due to its proprietary technology, which allows for precise genetic modifications, potentially leading to better therapeutic outcomes compared to competitors.
Progress in clinical trials for lead product candidates, particularly UCART123 for acute myeloid leukemia
Partnership announcements with major pharmaceutical companies
Regulatory approvals for new therapies
Market sentiment around gene editing technologies
Regulatory changes impacting gene therapy approvals
Technological disruption from emerging gene-editing technologies
Increased competition from other biotech firms developing similar gene-editing technologies
Potential for larger pharmaceutical companies to develop in-house capabilities
High cash burn rate leading to potential liquidity issues
Debt levels are concerning given the negative operating cash flow
moderate - While biotechnology can be somewhat insulated from economic cycles, funding for R&D and healthcare spending can be affected by broader economic conditions.
High interest rates can increase the cost of capital for biotechnology firms, impacting their ability to finance R&D and clinical trials, potentially leading to lower valuations.
minimal - Cellectis is not heavily reliant on debt financing, though its operational cash flow is negative.
growth - Investors are likely attracted to the potential for high returns from successful gene therapies.
high - The stock has shown significant price volatility, evidenced by a 177.6% return over the past year.